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Abstract 
HIV has become one of the most feared diseases in the world. It has claimed millions of 
lives, especially in Sub-Saharan Africa. Although it is impossible to cure, studies have 
shown that using antiretroviral therapy (ART) can greatly improve quality of life and 
decrease viral load. There are four main classes of ART—NRTIs, NNRTIs, protease 
inhibitors, and fusion inhibitors. Although access to ART is improving, it is vital that its 
use is increased in Sub-Saharan Africa, where the prevalence can be as high as 33%. 
This thesis explores the current need of ART in Sub-Saharan Africa, as well as 
the existing coverage. In addition, it addresses the obstacles preventing ART distribution 
and use—both provider and patient-related. Provider-related obstacles include limited 
availability of drugs, total cost, lack of healthcare staff and facilities, lack of organization, 
and government regulations. Patient-related obstacles include cost, transportation, 
geographic proximity to healthcare facilities, side effects and hunger, pill burden, 
hospital-related factors, cultural beliefs, social stigma, lack of adequate counseling, and 
drug resistance. It is important to be proactive, assess ART delivery, consider suggestions 
for improvement, and tackle the HIV epidemic.   
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Antiretroviral Therapy: Use in Sub-Saharan Africa  
and Common Obstacles Encountered 
The epidemic of human immunodeficiency virus (HIV) has torn apart many 
families and stolen many lives within the last 20 years. Every day, about 5700 people in 
the world die from AIDS and 6800 people become newly infected with HIV. 
Approximately two thirds of people living with HIV reside in Sub-Saharan Africa, 
making it the most seriously affected region in the world (UNAIDS/WHO, 2007). 
Providing treatment in this region and throughout the world is a major healthcare 
concern. There are currently four classes of drugs that have been formulated to target this 
virus. Even though none of these medications cure HIV, they have proved to drastically 
decrease viral load and improve the patient’s quality of life. In order to provide 
antiretroviral therapy in Sub-Saharan Africa, healthcare professionals first need to be 
familiar with HIV itself and the drugs that are available to treat it. Secondly, it is also 
important for them to assess the current need in their area and compare it with the percent 
receiving antiretroviral therapy. Finally, since there are many obstacles in distributing 
and maintaining treatment, it is imperative that they are identified and addressed so that 
this devastating epidemic can be brought to an end. 
Human Immunodeficiency Virus 
There are two different types of human immunodeficiency virus—HIV-1 and 
HIV-2. HIV-2 is found solely in West Africa, as opposed to HIV-1, which has 
documented cases worldwide. The majority of research has been done on HIV-1 since it 
is the more prevalent type of HIV. In order to produce medications to treat this 
devastating disease, the structure of the virus had to be understood as well as its 
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mechanism of infection. With this knowledge, particular drugs were devised to inhibit 
specific steps of the process (Lehne, 2007).   
Concerning its structure, the virus contains several main components: a core, a 
protein capsid and a lipid envelope. The core consists of single-stranded RNA and 
proteins (Lehne, 2007). See Figure 1.  
 
Figure 1. Structure of HIV Viron (NIAID, 2004) 
Viruses are not technically living organisms due to the fact that they rely on a host 
to assist in replication. HIV can enter the body through a variety of means. The most 
common modes of transmission include sexual intercourse, the use of contaminated 
needles, vertical transmission from mother to child, and breastfeeding (Vella & 
Palmisano, 2005). Regardless of how the virus is introduced to the body, HIV replicates 
and spreads in the same manner. Its first task is to locate a CD4 cell—a type of helper T 
lymphocyte. Once it finds one, glycoproteins (gp120 & gp41) on HIV’s envelope attach 
to specific proteins on the CD4 cells’ membrane. The membranes fuse and HIV injects its 
RNA into its new host (Lehne, 2007). An enzyme called reverse transcriptase transcribes 
 Antiretroviral Therapy 6 
the viral RNA into DNA. Then this DNA can be incorporated into the CD4 cell’s DNA. 
Therefore, the virus’ genetic material is replicated along with the CD4 cell’s DNA. This 
enables the virus to multiply itself. A daughter viron forms when the RNA and proteins 
migrate toward the edge of the cell and bud off. Final maturation occurs when large 
polyproteins in the viron are broken into smaller, functional proteins by an enzyme called 
protease. If this step is not completed, the viron is not infectious (Lehne, 2007). 
Once a person is infected with HIV, he or she may live up to 10 years without any 
signs of the disease. Despite the slow emergence of symptoms, the virus is rapidly 
replicating and destroying CD4 cells. In the initial phase on infection, there can be up to 
10 million virons per milliliter of blood. At this point, the individual has not mounted an 
immune response yet, allowing the virus to replicate unopposed. In addition, there is still 
a high CD4 count, which gives the HIV many vulnerable targets. Once the body’s 
immune system begins to attack, the number of virons per milliliter reduces to between 
1,000 and 10,000. Yet, this is still an astronomical number (Lehne, 2007). 
Drugs Available to Treat HIV 
 As the HIV epidemic spread globally, researchers recognized the immediate need 
for medicine. By studying the mechanism of the virus described briefly above, four main 
classes of medications were invented. These include NRTIs, NNRTIs, protease inhibitors, 
and fusion inhibitors (see Table 1). The treatment of HIV is called ART (antiretroviral 
therapy). It is generally recommended that patients are on regimens of three of four 
drugs. Using only one or two drugs is not typically prescribed because the probably of 
resistance is high. One possible exception is pregnant women (Lehne, 2007). Multiple 
studies have been conducted in order to determine the most effective regimens. These  
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have become known as HAART (Highly Active Antiretroviral Therapy) (Justesen,  
2005). 
 Table 1. Drugs of Antiretroviral Therapy  (Lehne, 2007) 
NRTIs Protease Inhibitors 
Abacavir  (Ziagen) 
Didanosine  (Videx) 
Emitricitabine  (Emtriva) 
Lamivudine  (Epivir) 
Stavudine  (Zerit) 
Tenofovir  (Viread) 
Zalcitabine  (Hivid) 
Zidovudine  (Retrovir) 
Acabavir/lamivudine  (Epzicom) 
Acabavir/lamivudine/zidovudine  (Trizivir) 
Emtricitabine/tenofovir  (Truvada) 
Zidovudine/lamivudine (Combivir) 
 
Amprenavir  (Agenerase) 
Atazanavir  (Reyataz) 
Fosamprenavir  (Lexiva) 
Indinavir  (Crixivan) 
Nelfinavir  (Viracept) 
Ritonavir  (Norvir) 
Saquinavir  (Invirase or Fortovase) 
Tipranavir  (Aptivus) 
Lopinavir/ritonavir  (Kaletra) 
NNRTIs Fusion Inhibitors 
Delavirdine  (Rescriptor) 
Efavirenz  (Sustiva) 
Nevirapine  (Viramune) 
 
Enfuvirtide (Fuzeon) 
 
The goals of HAART include the following: to diminish the viral load as much as 
possible, maximize the number of CD4 cells, restore and preserve immune function 
(reducing the risk of opportunistic infections), improve quality of life, and decrease 
mortality. The effectiveness of antiretroviral therapy has been very promising within the 
last couple of years. A patient on HAART should have a sharp drop in HIV RNA by the 
end of 8 weeks of therapy. In addition, HIV can often become undetectable (fewer than 
50 HIV RNA copies per mL) after 4 to 6 months. Even if this is the case, patients must 
continue following their drug regimen. Unfortunately, there is no complete cure for HIV 
or AIDS due to the fact that some virons remain dormant in CD4 cells (Lehne, 2007). 
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Nucleoside/Nucleotide Reverse Transcriptase Inhibitors 
Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) were the first HIV 
medications to be discovered. They have been considered the “backbone” of all 
antiretroviral regimens. They are convenient pills and have few drug interactions. The 
prototype of this class is zidovudine, which has been known to reach the CNS better than 
any other ART drug. Collectively, NRTIs are effective medications as a result of their 
structure—they are chemically similar to nucleosides (the building blocks of DNA). They 
can act as competitive inhibitors of reverse transcriptase. During transcription, reverse 
transcriptase uses the drug as a nucleoside, incorporating it into the DNA strand. This 
prevents other nucleosides from binding, which in turn terminates transcription (Lehne, 
2007 & Justesen, 2005). 
Non-nucleoside Reverse Transcriptase Inhibitors 
 A second class of ART that also inhibits reverse transcriptase is called a non-
nucleoside reverse transcriptase inhibitor (NRTI). Instead of acting like a nucleoside, it 
binds to an active site on reverse transcriptase, directly inhibiting it. Currently, efavirenz 
is the only NNRTI preferred for treating HIV. Typically, NNRTIs are given in 
combination with NRTIs and are administered in pill form. There are a couple 
disadvantages and limitations with the use of NNRTIs. First of all, resistance to this drug 
occurs more frequently than with any of the other classes. This is due to the high rate of 
mutation. It is estimated that 10 incorrect base pairs are incorporated into viral DNA 
during every replication. Secondly, it is only used for HIV-1; it is ineffective in treating  
HIV-2 (Lehne, 2007 & Justesen, 2005). 
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Protease Inhibitors 
 Protease inhibitors (PIs) are known as the most effective antiretroviral drugs. 
They are also given in pill form. When given in combination with NRTIs, the viral load is 
often undetectable. Sometimes it will also be given with a second PI, which boosts its 
effects. Concerning their mechanism of action, they inhibit the last step of viral 
replication (when an enzyme called protease breaks large polyproteins into smaller, 
functional proteins).  If a patient is on a protease inhibitor, the drug binds to active sites 
on protease which makes it inactive. This leaves the viron immature and unable to 
become infectious. There are many positive aspects about using a PI—it is less selective 
than some of the other drugs, treats both HIV-1 and HIV-2, and can be used to treat 
children. Lopinavir can be used in infants as young as 6 months old and nelfinavir in 
children at least two years old. Another valuable use for PIs is in some resistant cases. 
Tipranavir/ritonavir (a combination drug) is flexible and is able to adapt the shape of HIV 
as it mutates. Therefore, it can effectively halt viral replication in resistant cases. A 
negative aspect of protease inhibitors is that it can cause multiple drug interactions by 
increasing other drug levels (Lehne, 2007 & Justesen, 2005). 
Fusion Inhibitors 
 The only fusion inhibitor is enfuvirtide, also known as T-20. Unlike all of the 
other classes of antiretroviral drugs that work by inhibiting enzymes, this one actually 
stops HIV from entering into the CD4 cells. It binds to gp41 on the virus, stiffening the 
glycoprotein. Since it is no longer able to mold into other shapes, it is unable to fuse with 
the CD4 cells’ membranes. This halts infection. The positive aspects of using a fusion 
inhibitor is that it is often very effective, it can be useful for patients with a resistant 
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strain of HIV, and it has few known drug interactions Unfortunately, this medication is 
not as widely used because it is inconvenient and expensive. It takes 106 steps to make 
this drug (in contrast to the 8-12 steps required for NRTIs, NNRTIs and PIs). Therefore, 
the cost is high—approximately US$20,000 per year. In addition, fusion inhibitors are 
inconvenient because they require two subcutaneous shots every day. It is also limited to 
HIV-1 and children over age 6 (Lehne, 2007 & Justesen, 2005). 
Preferred Regimen 
 The preferred HAART regimens are listed below in table 2 (Lehne, 2007).  
Table 2. Preferred HAART Regimens (Lehne, 2007) 
Regimen Drugs of the Regimen 
NNRTI based 
(1 NNRTI + 2NRTIs) 
Efavirenz + (lamivudine or emtricitabine) + (zidovudine or 
tenofovir) 
PI based 
(1 PI + 2 NRTIs) 
Lopinavir/ritonavir (Kaletra) + (lamivudine or emtricitabine) + 
zidovudine 
 
The Need for Antiretroviral Therapy in Sub-Saharan Africa 
In order to provide HIV treatment, healthcare professionals need to assess the 
need in their area and compare it to the percent of patients who are receiving ART. The 
United Nations Programme of HIV/AIDS (UNAIDS) and the World Health Organization 
(WHO) have compiled statistics to provide healthcare providers with this information. 
The map in Figure 2 displays the prevalence of HIV/AIDS throughout the world.   
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Figure 2. Prevalence of HIV/AIDS in 2006 
(Retrieved from the WHO website: http://gamapserver.who.int/mapLibrary/Files/Maps/HIVPrevalence 
Global2006.png).   
 
Concerning total need, they estimated that there were 33.2 million people in the world 
living with HIV in the year 2007. 22.5 million of these people (two thirds) were from 
Sub-Saharan Africa. In addition, nearly 90% of the children in the world infected with 
HIV live in this region. Concerning mortality, 2.1 million of people in the world died of 
AIDS in 2007. 1.6 million of these people were Sub-Saharan Africans. This means that 
three quarters of all deaths from AIDS were in this region. In fact, AIDS is the leading 
cause of death in Sub-Saharan Africa. (UNAIDS/WHO, 2007). HIV/AIDS has drastically 
reduced the life expectancy in some of these countries. For instance, in South Africa, the 
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male life expectancy dropped from 61.5 in 1994 to 49.2 in 2000. This decline was mainly 
due to the increasing prevalence of HIV/AIDS cases (Kapp, 2004).  
Approximately 5% of people in Sub-Saharan Africa are infected with HIV, which 
is drastically higher than the rest of the world (<1%). However, the prevalence varies 
greatly county to country (see table 3) (UNAIDS/WHO, 2007). 
Table 3. Prevalence of HIV Reported in the 2006 WHO Report on the Global AIDS 
Epidemic (UNAIDS/WHO, 2007) 
Country          % of 
Population 
Country          % of 
Population  
Country        % of 
Population 
Benin                          1.8 Ethiopia                      1.4 Senegal                     0.9 
Botswana                  24.1 Ghana                         2.3 Sierra Leone             1.6 
Burkina Faso              2.0 Guinea                        1.5 South Africa           18.8 
Burundi                      3.3 Kenya                         6.1 Swaziland               33.4 
Cameroon                   5.4 Lesotho                    23.2 Uganda                     6.7 
Central African Republic   
                                 10.7 
Malawi                     14.1  Tanzania                   6.5 
Chad                           3.5 Mali                            1.7 Zambia                   17.0 
Cote d’lvoire              7.1 Niger                          1.1 Zimbabwe              20.1 
Equatorial Guinea      3.2 Rwanda                      3.1  
  
The majority of the countries in Sub-Saharan Africa that have a high prevalence of HIV 
are in located in southern Africa. Countries of particular concern include Swaziland (who 
has a prevalence of 33.4%), Botswana (24.1%), Lesotho (23.2%), Zimbabwe (20.1%), 
South Africa (18.8%), and Zambia (17%). The prevalence of HIV in the countries of East 
Africa have been relatively stable, and are even beginning to decline. This is the same for 
many of the countries in West and Central Africa (UNAIDS/WHO, 2007). Organizations 
such as the WHO and UNAIDS use this information to narrow in on the areas with the 
greatest need.  
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Use of ART in Sub-Saharan Africa 
As a result of increased awareness and funding, the distribution of ART in Sub-
Saharan Africa has been improving substantially. This has greatly improved the clinical 
outcome of the disease and reduced the death rate. Although the patients will have to 
remain on ART for the rest of their lives, their ability to live and function in society is 
greatly improved. Many patients make a complete turnaround and no longer display 
outward signs and symptoms of HIV. In addition, many patients’ viral loads diminish to 
undetectable levels. However, one of the major problems in Sub-Saharan Africa is that 
the majority of people are not tested for the disease. In fact, less than 10% of HIV-
infected people in this region know that they are HIV positive. Most people with HIV are 
not tested for it until they are admitted into the hospital for opportunistic infections 
(Colebunders, Ronald, Katabira, & Sande, 2005).  
Still, as education and prevention are promoted, more and more patients are being 
tested for HIV. Once HIV is diagnosed and the patient’s disease is staged, the physician 
determines the patient’s need for antiretroviral therapy. The World Health Organization 
(WHO) recommends that in resource-limited settings, ART is given to patients who fall 
in one of these categories: 
• Stage I or II HIV with a CD4 cell count below 200/mm3 
• Stage III HIV with a CD4 cell count below 350/mm3 
• Stage IV HIV  
These recommendations are in place to help guide physicians in providing ART in areas  
where there are not enough resources and for every HIV patient to receive therapy  
(WHO, 2003).  
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The recommended regimens for Africa usually include one NNRTI and two NRTIs. 
These drugs are cheaper and more accessible in developing countries (Colebunders, 
Ronald, Katabira, & Sande, 2005).  The WHO recommends using one of the following 
regimens:  
• stavudine + lamivudine + neverapine 
• zidovudine + lamivudine + neverapine 
• stavudine + lamivudine + efavirenz 
• zidovudine + lamivudine + efavirenz  (WHO, 2003) 
A study in Botswana collected information and compiled statistics about the use 
of the different types of ART. Of ART receivers, 31% were taking a combination of at 
least three drugs (18% on PI regimen plus 13% on NNRTI regimen). From the rest of the 
patients, 52% were only able to afford one drug or a combination of two drugs. The most 
common class of drug given by itself was an NRTI. The remaining regimens (17%) were 
unclear (Weiser, Wolfe, Bangsberg, Thior, Gilbert, Makhema, 2003). Studies such as this 
one are important because they provide data that can be further researched to determine 
effectiveness of drug regimens.  
It is very important that HIV drug coverage is analyzed and evaluated on an 
annual basis. The number of HIV-infected people living in Sub-Saharan Africa needs to 
be compared to the number of patients that are receiving ART. This will provide data 
regarding the current state of ART distribution. Therefore it helps to ensure that 
distribution is increasing and maintenance is improving. Figure 3 shows the coverage in 
Sub-Saharan Africa in the year 2006.         
 
 Antiretroviral Therapy 15 
 
Figure 3. ART Coverage in Sub-Saharan Africa in 2006 
(Retrieved from the WHO website: http://gamapserver.who.int/mapLibrary/Files/Maps/Africa_ARV 
Coverage_A4_100407.png).  
 
In 2003, the WHO declared a goal of reaching 3 million HIV patients by the year 
2005. It was called the “3 by 5” initiative. Although, the goal was not met, there was a 
drastic improvement in the distribution of antiretroviral therapy. In 2003, only about 
400,000 HIV patients from low or middle-income countries were receiving ART. By the 
year 2005, this increased to 1.3 million people. In Sub-Saharan Africa, the number of 
patients on ART increased drastically from 100,000 to 810,000 between 2003 and 2005 
(see table 4) (WHO/UNAIDS, 2006).  In the year 2007 1.3 million people in this region 
were on ART. This is approximately 28% of their HIV population. Currently, the WHO 
and UNAIDS are pushing towards universal access by 2010.  (WHO/UNAIDS, 2007).  
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  Table 4. Estimated Distribution of ART in Sub-Saharan Africa for 2005 
Country HIV  patients 
in need of ART 
HIV patients who 
received ART 
ART 
coverage 
SOUTHERN AFRICA 
Angola 52,000 2500-3500 6% 
Botswana 84,000 67,000-77,000 85% 
Lesotho 58,000 7,500-9,000 14% 
Madagascar 20,000 <200 0% 
Malawi 169,000 31,000-35,000 20% 
Mauritius --- <200 --- 
Mozambique 216,000 19,000-21,000 9% 
Namibia 41,000 27,000-31,000 71% 
South Africa 983,000 178,000-235,000 21% 
Swaziland 42,000 12,000-14,000 31% 
Zambia 183,000 45,000-52,000 27% 
Zimbabwe 321,000 22,000-27,000 8% 
EAST AFRICA 
Burundi 46,000 6,000-7,000 14% 
Eritrea 11,000 <1000 5% 
Ethiopia 278,000 19,000-22,000 7% 
Kenya 273,000 60,000-72,000 24% 
Rwanda 49,000 18,000-20,000 39% 
Somalia 6,000 --- 1% 
Uganda 148,000 71,000-79,000 51% 
United Republic 
of Tanzania 
315,000 20,000-23,000 7% 
WEST AFRICA 
Benin 14,000 3,500-6,000 33% 
Burkina Faso 34,000 7,500-9,000 24% 
Cameroon 108,000 21,000-26,000 22% 
Cote d’Ivoire 111,000 18,000-19,000 17% 
Gambia 1,500 <200 10% 
Ghana 61,000 4,000-5,000 7% 
Guinea 23,000 2,000-2,500 9% 
Liberia 15,000 <500 3% 
Mali 22,000 5,500-9,000 32% 
Niger 12,000 <1,000 5% 
Nigeria 636,000 37,000-45,000 7% 
Senegal 9,000 3,000-5,500 47% 
Sierra Leone  9,600 <500 2% 
Togo 25,000 5,000-8,000 27% 
CENTRAL AFRICA 
Central African 
Republic 
49,000 1,500-2,000 3% 
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Chad 38,000 5,000-8,000 17% 
Democratic Republic of 
the Congo 
209,000 7,000-8,500 4% 
 
(WHO/UNAIDS, 2006). 
Obstacles for Providing Treatment 
 In order to effectively treat HIV patients in Sub-Saharan Africa, it is important to 
tackle the common obstacles to providing ART. There are two main types of obstacles: 
provider-related obstacles and patient-related obstacles. Provider-related obstacles 
include limited availability of drugs, total cost, lack of healthcare staff/heavy workloads, 
lack of healthcare facilities, lack of organization, and government regulations. Patient-
related obstacles are typically related to adherence to the drug regimen. They can include 
cost, transportation, geographic proximity to healthcare facilities, side effects and hunger, 
pill burden, hospital-related factors, cultural beliefs, social stigma, lack of adequate 
counseling, and lastly, drug resistance. Addressing these obstacles will help to provide 
successful treatment to the maximum number of patients.  
In order to supplement my research, I attempted to administer a survey (see 
Appendix A) to healthcare providers in Africa. Unfortunately the response was poor. I 
sent ten surveys to healthcare providers within a missions organization; I only received 
one survey back. Despite the fact that this eliminates my ability to compare obstacles 
between different countries, it did provide specific information on a hospital in Benin. 
The government in Benin had begun to provide ART to this hospital in 2005; since then, 
57 patients had been treated. Although they had access to NNRTIs, NRTIs and protease 
inhibitors, their most common regimen was a NNRTI plus a NRTI. The obstacles 
encountered in this hospital will be provided throughout the remainder of this thesis in  
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conjunction with a review of existing studies.  
Provider-Related Obstacles 
Limited Availability of Drugs 
As mentioned above (see Table 4), there are more HIV patients than the current 
resources, drugs and healthcare facilities can supply. Only a limited number of patients 
can be treated. This is one of the obstacles in providing antiretroviral therapy. In the 
hospital in Benin that participated in my survey, approximately 80% of people seeking 
HIV treatment were able to receive it through the hospital. This percent does not include 
people with HIV who do not seek treatment. The reason why 100% of HIV patients were 
not able to receive treatment is because the supplies and medications were limited. It is 
also important to note that if patients become resistant, there is an even lower chance that 
the second-line drugs will be available for them. Many of these patients will progress 
quickly in the disease due to a lack of effective treatment.  
High Cost 
 Since finances are an obvious limitation to providing drug therapy in resource-
poor settings, multiple organizations have published an estimate of the total cost. 
Gutierrez, et. all complied information on what it would cost to see “3 by 5” come to 
completion. They calculated the costs for the 34 countries that made up 90% of the 
overall need. The estimate that they arrived at was a range from $5.1 billion to $5.9 
billion. This was just to include the money that would be spent between 2003 and 2005. 
They also included a chart of the distribution of this money: 43% for ART, 17.8% for 
treating opportunistic infections, 12.2% for support costs (training health personnel, 
supervision, etc), 10.1% for universal precautions, 9.1% for palliative care, 3.9% for 
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program costs, 1.8% for opportunistic infection prophylaxis, 1.4% for ART monitoring 
and laboratory costs, and 0.6% for testing and counseling. Concerning the costs of ART 
in resource poor settings, first line therapy ranged from US$140 to US$304 per patient 
per year. Second line therapy ranged from US$510 to US$1108. The costs then increased 
even more for patients who were also diagnosed with TB or were pregnant (Gutierrez, 
Johns, Adam, Bertozzi, Edejer, Greener, et al., 2004).  
 An even higher estimate has been released by the World Health Organization. 
They estimated that for the year 2007, it would cost approximately $18.1 billion to treat 
HIV globally. However, it was estimated that only about $10 billion dollars would be 
available. The budget for the World Health Organization’s HIV/AIDS work has also been 
short. From their needed $281 million, they were $120 million short. Therefore, their 
research and impact was limited as well (WHO, 2006).  
 Concerning the current source of the needed money, many governments, 
organizations, and outside donors contribute to the funding. The WHO estimated that in 
the year 2006, about $8.9 billion came from existing pledges and commitments, and $2.8 
billion came from domestic sources. In some middle- and upper-income countries, the 
government covers 80-95% of HIV costs through public health programs and social 
security. Financial support is crucial for some low- to middle- income countries. 
However, even after combining the government’s own funding and outside funding, only 
about 25-50% of the costs are typically covered. The rest has to be covered by the 
patients or their families (WHO, 2006). This shows how finances are one of the main 
barriers to reaching universal access to ART.  
One way that the obstacle of cost can be addressed is to raise awareness. This can  
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be done through a variety of means such as publications to the general public, news 
reports on television, and using influential people as spokespersons. Both the cost of 
providing ART and the current funding available need to be announced. It is also 
important that funding is coordinated well. There are currently many programs and 
organizations raising money for the HIV/AIDS crisis. They need to be overseen and 
organized so that the resources are mobilized to where the need is.  
Lack of Healthcare Facilities and Skilled Healthcare Workers 
In order to effectively provide antiretroviral therapy, there must be a large base of 
healthcare facilities and workers that are willing to participate. Healthcare providers are 
the connection between the public and current medicine and technology. Unfortunately, 
there is a lack of healthcare providers in Sub-Saharan Africa. This results in understaffing 
of hospitals and clinics. In addition, since there are not sufficient numbers of healthcare 
workers, new hospitals and clinics cannot be started. As a result, there are many people in 
rural villages and towns that cannot receive medical care because there is not a healthcare 
facility close enough to their home. In order to increase the number of healthcare 
facilities dispersed in low-income countries, money must be raised and workers must be 
recruited. 
Compared to the rest of the world, Sub-Saharan Africa is lagging behind in their 
workforce. Even though Africa has 14% of the world’s population and 25% of the 
disease burden, they only have 1.3% of the health workers. On average, there are 0.8 
health workers per 1000 people. The world’s average is more than quadruple this statistic 
(4.2 per 1000 people). The WHO regional director for Africa stated that “Africa is 
literally engaged in a war against diseases and health challenges of all descriptions—old,  
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neglected, emerging, and re-emerging. This war cannot be fought without soldiers!”  
(Sambo, 2007, p. 5).   
There are multiple reasons why the health workforce is struggling. First of all, the 
human resource departments in countries of Sub-Saharan Africa are lacking in structure 
and organization. They often lack policies, are poor at planning, and have weak 
management. In addition, they usually have inadequate incentive systems. It is a struggle 
for these departments to recruit and retain workers for the healthcare field (Lusamba-
Dikassa, 2007). 
Secondly, they often do not have the resources to adequately train and pay health 
workers. Healthcare providers in Sub-Saharan Africa have very low salaries compared to 
those in other countries. Therefore, recruiting for this region is difficult. Not only are 
there insufficient funds for paying workers, but there are also not enough funds to cover 
the cost of training. This can jeopardize the quality of training. The easiest place to train 
healthcare workers is in the hospitals. Unfortunately, healthcare students who only 
receive training in hospitals do not learn much about disease prevention and health 
promotion. Instead, all of their training is based upon diagnoses and treatment. Therefore, 
there is often a lack of holistic care. This affects the healthcare workers’ ability to educate 
patients about HIV prevention. With more investment in healthcare training, institutions 
could be evaluated and improved (Lusamba-Dikassa, 2007). 
Thirdly, it is hard to recruit people to the health field, and even harder to keep 
them there. Since there are few healthcare providers, the workload is high, especially in 
the hospitals. This puts a large burden on the staff because they must provide care for so 
many patients that they become overworked. A study in Tanzania showed that 82% of 
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healthcare workers in Tanzania felt like they were overworked (Hardon, Akurut, Comoro, 
Ekelzie, Irunde, Gerrits, et al., 2007). Being a healthcare professional can be very 
frustrating and stressful. The combination of physical, emotional and mental stress often 
leads to fatigue and burn-out. Therefore, this makes medical professions less attractive. In 
Sub-Saharan Africa this leads to a high migration rate. Many healthcare workers leave 
this region to work in countries where there is a better established healthcare system. This 
is often attractive because workload is usually less, pay is better, and there are more 
benefits and incentives (Marchal, De Brouwere, Kegels, 2005). Rates of migration in 
African countries can be as high as 60% (Lusamba-Dikassa, 2007). According to the 
South African Medical Association, more than 4000 doctors left the public health system 
between 2000 and 2004. They either went abroad or started a private practice. This 
roughly equaled the number of doctors trained within that time (Kapp, 2004).  
Finally, HIV has a direct effect on the health workforce. Besides claiming the 
lives of many healthcare workers, it also affects the morale and attitude of current 
healthcare workers. The percent of HIV positive patients in the hospitals is on the rise, 
which makes it worse. Currently about 46% of patients admitted into hospitals in South 
Africa are HIV positive. Research has shown that AIDS patients stay almost twice as 
long as patients without AIDS. In one study, AIDS patients stayed in the hospital an 
average of 13.7 days. Non-AIDS patients were admitted in hospital for an average of 8.2 
days. Therefore, this shows that this disease dramatically increases the need for medical 
care. This leads to a high workload, stress, and fatigue. In addition, most patients with 
HIV/AIDS are brought to the hospital in advanced stages of the disease. High death rates 
among these patients lead to a sense of helplessness among healthcare workers (Marchal,  
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De Brouwere, Kegels, 2005). 
Fear of being exposed to HIV is an additional reason why it is hard to recruit and 
maintain healthcare workers. Even though the actual risk of HIV transmission after 
percutaneous exposure is only about 0.3%, the perceived risk is much higher. Often there 
are inadequate supplies (such as gloves, gowns and disinfectant) for healthcare providers 
to use to protect themselves. This instills fear in current healthcare workers, which then 
affects the quality of care that HIV patients receive. It also deters potential healthcare 
workers (Marchal, De Brouwere, Kegels, 2005). 
Even if health workers do maintain their positions, the heavy workload and high 
stress effects the care that they are able to give to their patients. The morale of current 
health workers is often very low and it is hard to provide motivation. As a result, patients 
often do not receive quality care. Quality care is no longer amongst the healthcare 
workers’ main concerns. This is especially true for patients with HIV who are sometimes 
neglected as a result of the healthcare worker’s fear of exposure. The low morale also 
leads to a high rate of absenteeism (Marchal, De Brouwere, Kegels, 2005). 
In order to improve morale and patient care, it is imperative that the shortage of 
healthcare providers is addressed. Steps need to be taken to decrease the workload, 
reduce the risk of exposure (and the fear associated with it), and reduce the rate of 
migration of healthcare workers. In order to decrease the risk of exposure, universal 
precautions need to be maintained on a stricter level. Facilities need to make it a priority 
to provide all their staff with gloves, gowns, and goggles and to provide a safe way to 
dispose of used needles and contaminated items. It is also important to adopt safer 
nursing and medical techniques according to current research. Finally, post-exposure 
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prophylaxis should be provided to healthcare workers free of charge (Marchal, De 
Brouwere, Kegels, 2005). Adhering to these practices will help provide safety as well as 
reduce fear. An additional way to reduce fear among healthcare workers is to provide 
training about safe techniques as well as additional education about HIV. Since the 
perceived risk is often much higher than actual risk, more education would help to reduce 
the fear associated with exposure to HIV.  
It is vital that these people work in the areas of greatest need. One way to improve 
the retention of healthcare workers in smaller rural towns and villages is to recruit people 
who live in particular towns or villages that are in need. These people can be trained in 
larger cities and then return to their original home. Since they would have family and 
friends in this area, it would be more likely that they would stay. Due to the fact that most 
people in these rural areas would not be able to afford medical training, funds need to be 
raised to provide scholarships and grants for their training.  
It is also important that additional incentives are provided so that the medical field 
in Sub-Saharan Africa becomes more attractive to healthcare workers. This will reduce 
the rate of migration of healthcare workers out of Africa. One possible incentive is to 
provide medical or nursing education at a reduced cost if students agree to work a certain 
number of years in a particular location that needs healthcare workers.  
In order to address the large workload, additional people need to be recruited to 
join the medical field. For this come to fruition, effort needs to be put into the human 
resource departments. Three of the main goals that HR departments should strive for are 
improved planning and formation of policies, enhanced management, and better training 
of staff. It is essential that progress is monitored and evaluated. Countries need to help 
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human resource departments achieve these by allocating money, showing their political 
commitment, and helping to raise awareness. Not only does each individual country need 
to take leadership over the issue, but they need to be willing work collectively with other 
countries and global organizations to discuss the most effective ways of enhancing 
human resource departments (Lusamba-Dikassa, 2007). 
Lack of Organization 
Weiser said in his research study that it is important to “strengthen the health 
infrastructures for delivering care” (Weiser, et al., 2003).  In resource-poor countries 
there is usually poor organization within the health field. As opposed to more developed 
countries such as the United States, countries in Sub-Saharan Africa do not have very 
well designed healthcare systems. Many do not have well planned programs, policies, 
and procedures. Countries usually have to rely on plans and procedures suggested by 
international organizations. They need to take it a step further by researching and 
determining what works best for their country. Then they need to outline and organize 
this information and amend policies and procedures as needed.  
Poor organization often leads to poor communication. This has been an additional 
challenge in Sub-Saharan Africa. If communication between the different healthcare 
levels is lacking, reporting becomes more challenging. Therefore, it is difficult to put 
together databases and study the epidemiology. In addition, also makes it difficult to 
evaluate performance. Therefore, there is often a lack of accountability.  
I have come across poor reporting and participation in research through my own 
data collection. As stated above, I sent out 10 surveys regarding ART use and common 
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obstacles encountered to healthcare professionals in different African countries. The 
response was very poor; only one survey was returned.  
Government Regulations Regarding ART  
The extent of government involvement in HIV treatment varies greatly from  
country to country. Government regulations can sometimes become obstacles to 
healthcare providers. For instance, in Benin, the government selects which hospitals that 
they will supply ART for. The remaining hospitals are unable to provide treatment for 
their HIV patients. The selected hospitals have rules that they are supposed to follow, 
regardless of if they are feasible or not. The nurse who completed my survey in Benin 
said the following:  
They have certain rules for following up with labtests, which I cannot always do, 
since in our lab we cannot do the tests and they don't supply us with any money 
for travelling elsewhere. (CD 4 and viral charge). There is also a whole pile of 
paperwork to be done each month.  
It was also mentioned that the government comes to check on their stock on a regular 
basis. However, they have run out on several occasions. Even though governement 
resources are necessary for HIV treatment, it is important to evaluate the government’s 
regulations. It is important for them to address impractical or outdated regulations and 
procedures.  
Patient-Related Obstacles 
Regardless of how efficient a country is at distributing ART, many patients face 
multiple obstacles of their own, which drastically affects HIV treatment. According to a 
study by Mshana, et al. in Tanzania, the top three areas of concern by potential ART 
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recipients were “financial constraints, reaching the regional hospital and sustaining 
treatment” (Mshana, Wamoyi, Busza, Zaba, Changalucha, Kaluvya, et al., 2006). Each of  
these factors affect how well the patients are able to adhere to their drug regimens.  
Patient Adherence to Drug Regimen 
Consistent adherence to the drug regimen is a vital factor in treating HIV/AIDS. 
Optimal adherence is greater than 95%.  This means that a patient can only miss one dose 
in 10 days if he or she is on a twice-a-day regimen (Weiser, et al., 2003).  If adherence is 
poor (<80%), the drugs are not maintained at high enough concentrations to stop HIV 
replication. This leads to detectable viremia, poor treatment outcomes, and even drug 
resistance. A study of 45 HIV-infected patients determined that 87% of patients with less 
than 80% adherence went into virologic failure (Chesney, 2000).  Even nonadherence for 
as short of a time as a week can result in rapid rebound of the virus (Weiser, et al., 2003).  
There have been multiple studies that investigated adherence rates of countries in 
Sub-Saharan Africa. A study conducted by Hardon, et al. in Botswana, Tanzania, and 
Uganda in 2007 estimated that 77% of African patients adhere to the drug regimen 
(Hardon, et al., 2007). However, according to a study by Weiser, et al., the levels of 
adherence in Boswana were significantly lower. Using questionnaires and interviews they 
collected data from 109 HIV patients and 60 healthcare providers in Botswana. 
According to patients’ self-report, 54% of patients were adherent, 17% were non-
adherent and 29% had gaps in treatment. Healthcare providers estimated that 56% of their 
patients were adherent and 44% were non-adherent (Weiser, et al., 2003).  
In developed countries such as the United States, poor adherence usually stems 
from substance abuse, dietary restrictions, the “pill burden,” and side effects. However, 
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research has shown that economic factors predominate poor adherence in resource-poor 
settings (Chesney, 2000). It is actually rare that lack of motivation leads to poor 
adherence. In fact, studies show that Africans are actually highly motivated to take their 
medications as prescribed. However, there are many other constraints that limit their 
ability to do so (Hardon, et al., 2007).  
Many of the barriers to ART adherence were documented the study mentioned 
above by Weiser, et al.  They chose Botswana to collect their research because of the 
high prevalence of HIV—the highest in the world. In fact, 60% of their hospital beds are 
occupied by AIDS patients (Weiser, et al., 2003). The top reasons they listed for non-
adherence are included in Table 5.  
Table 5. Reasons Stated by Patients for Non-adherence (Weiser, et al., 2003) 
Reason Percent of 
Patients 
Reason Percent of 
Patients 
Finances 48% Hard to follow instructions 5% 
Forgetting 29% Too sick  4% 
Ran out of medicine 17% Misunderstanding doctor 3% 
Travel 13% Pharmacy closed 3% 
Side effects 12% Stigma 3% 
Too busy 12% Alcohol 1% 
Doctor’s orders 8% Felt better 1% 
Distance from clinic 5% Stresses at home/work 1% 
 
It is also interesting to note that gaps in treatment were more common than day-to-day 
non-adherence. This shows that patients are motivated to take their medication on a 
regular basis. It is more common that barriers (such as cost or transportation) prevent 
them from receiving their next supply of medication (Weiser, et al., 2003). 
 Concerning the adherence of HIV patients in Benin, the nurse who filled out my 
survey stated the following:  
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Most people are very keen to start treatment when they are very sick, but we have 
seen some non-adherence by some of them when they were better. We have 
decided not to put people on treatment anymore, unless we know where they live 
and they have to sign an agreement before we start treatment with one other 
member of their family or a friend present. This makes it easier to check up on 
them when they don't show up for appointments. 
Poor adherence in this hospital in Benin predominantly stemmed from the following 
obstacles: lack of funds, geographic proximity to healthcare facility, and social/cultural 
issues. Since they had only been distributing ART for two years, there was little data 
about resistance. In addition, they had no way to test for resistance.  
Although the major obstacles to optimal adherence will vary from country to 
country, it is still important to analyze each one. The remainder of this thesis will provide 
current research about the following obstacles: cost, transportation, proximity to 
healthcare facilities, side effects and hunger, hospital-related factors, cultural beliefs, 
social stigma, pill burden, lack of adequate counseling, and lastly, drug resistance.  
Cost 
The most widely mentioned barrier is cost. Many people with HIV will not seek  
out treatment at all because they assume it will be too expensive. Even if they do seek out 
treatment, many patients in rural towns and villages of Sub-Saharan Africa are unable to 
pay. A patient interviewed in Mshana’s study said the following: “If you go to Bugando 
without money, they will completely not care about you…there are good services if you 
have money, but if you don’t have money, the services are not good” (Mshana, et al., 
2006, p. 653).  
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As a result of the increasing awareness regarding HIV/AIDS in Sub-Saharan 
Africa, funding is being increased to assist patients paying for ART. In fact, many 
governments and organizations are beginning to provide ART free of charge. However, 
this is not the case in all areas. In 2003, when Weiser et al. completed their study in 
Botswana, patients were only receiving about one third of the cost of optimal ART. 
Medical aid programs supplied up to 1,000 pula each month. However, the cost of a 3-
drug regimen ranged from 2,000 to 4,000 pula per month. If patients were able to afford 
therapy at all, many of them had to resort to sub-optimal therapy, which was usually a 
regimen of only one or two drugs. It was estimated that if cost was eliminated as an 
obstacle for the patients in this study, good adherence would increase from 54-56% to 
74% of the patients (Weiser, et al., 2003).  
Even if the government or a nonprofit organization pays for the cost of ART, 
there are still additional expenses that make it difficult for patients to afford their HIV 
treatment. Many clinics and hospitals charge a registration fee or visit fees each time they 
come to pick up the medication. In addition, often there are laboratory fees. These can be 
difficult for patients with low incomes to pay. For instance, in one of the facilities in 
Tanzania that participated in Hardon’s study, there was a visit fee up to US$3 and a 
US$15 lab fee (Hardon, et al., 2007).  However, the average daily wage in this country is 
only about US$1.40 per day (Wikipedia, 2007 & Currency Converter, 2007). This would 
cost approximately 13 days wages! In addition, these patients often lose an entire day’s 
wages on the day that they visit the clinic or hospital (Hardon, et al., 2007).   
 Even if patients have enough money to cover these expenses, they may choose not 
to continue with their drug regimen because they have other unrelated expenses that they 
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would not be able to cover. It is important that these patients have enough remaining 
money to care for their families—providing them with food, clothing and shelter. These 
obligations are of more importance to them than their HIV treatment (Weiser, et al., 
2003). It is important that additional funds are raised to help patients pay for some of 
these additional expenses. This will improve patient adherence overall. One way to do 
this on an individual basis is through sponsorship programs. Families throughout the 
world can sponsor an HIV patient, supplying extra money so that the patient can pay for 
transportation, hospital fees, food, and additional costs.  
Transportation 
Transportation costs can also be a burden on patients. Some patients fail to make 
it to follow-up visits where they would have received a refill on their medication. Most 
Africans do not own a vehicle, therefore they must pay for a bus or taxi. For long 
distances in Uganda, transportation can cost 30,000 shillings (US$17) round trip (Hardon, 
et al., 2007). The average Ugandan only makes 42,000 shillings (US$24) per month 
(Stoker, 2005). Therefore, this is huge cost! In addition to the cost of transportation, the 
inconsistency and unreliability of transportation can make patients late. This means that 
they may run out of pills before they are able to get back to the clinic or hospital. Overall, 
cost and transportation are two of the main causes of sub-optimal adherence (Hardon, et 
al., 2007).  
If it is possible to raise additional funds, some of the money raised can be used to 
help patients reach the healthcare facilities. However, since money is also one of the 
largest obstacles this will probably not be an option for most countries. Another idea is to 
buy a large van or other vehicle to pick up patients and provide transportation for follow-
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up visits. This will work best in towns where there is a large need and the distance 
between patients’ homes is not very far.  
Geographic Proximity to Treatment Facility  
Another hindrance for people who need ART is that there is often not a healthcare 
facility close enough for them to go to. As discussed above, this problem stems from the 
fact that most countries are lacking in resources and in their number of healthcare 
professionals. Some patients from Weiser et al.’s study said that they had to travel 800-
1000 km in order to reach the clinic or hospital. It was very difficult for them to do this 
on a monthly basis (Weiser, et al., 2003). Even if there are closer hospitals and clinics, 
many do not have the ability to test and treat HIV. There are many villages dispersed 
throughout the Africa countries. Many are 100 km or more from cities where ART is 
provided. Therefore, even if an HIV patient can make it to a healthcare facility once, it 
will be difficult for him or her to go for follow-up visits every month to pick of more 
medication. This leads to poor adherence. It is important that countries as a whole assess 
their need for additional healthcare facilities based upon the need in various locations. 
(Hardon, et al., 2007). 
Side Effects and Hunger 
Sometimes side effects that the patients experience can lead to poor adherence to 
the drug regimen. Usually the side effects dissipate with time; however, some patients do 
not know this. The most common side effects include headache, nausea, vomiting, 
diarrhea, increased heart rate, rash, and swollen legs. If the effects are bad enough, some 
patients will begin skipping doses, or quit altogether. Some patients will only take their 
pill once a day instead of twice a day in order to alleviate some of the symptoms. In 
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addition, sometimes the symptoms (such as sweating) are embarrassing, so patients will 
not want to take the medication when they are out in public. This is another reason why  
some patients skip doses (Hardon, et al., 2007). 
 Nearly every patient will experience side effects; however, they will be more 
extreme in some patients than in others. Healthcare providers need to monitor their 
patients for side effects. The patients who experience very mild side effects may be able 
to live with the side effects. However, for the patients with severe side effects, healthcare 
providers should look into other regimens. Adherence will improve if the symptoms with 
the new regimen are less severe. It is also important that healthcare providers inform their 
patients that some side effects will gradually dissipate over time. This will encourage 
patients to remain adherent at the beginning of their regimens. If major side effects do not 
wear off, they should notify their healthcare provider so that other regimens can be 
explored. 
Many patients on ART also complain of hunger during the initial stages of 
treatment. As the body is regaining its weight and strength, it requires extra food 
(Hardon, et al., 2007).  It is also recommended that these patients eat a well-balanced 
meal, which usually means they have to buy more expensive food. Patients in rural towns 
and villages do not have the resources to buy supplemental food, or an increased quantity 
of food. Often they will have a limited food supply at home and are unable to satisfy their 
appetites. The hunger can become so bad that patients don’t want to take their 
medication. A male participant in Mshana’s study can be quoted as follows: “you take 
those medicines, they can overpower you, so you find it is just better to leave them, due 
to lack of that food you need” (Mshana, et al., 2006, p. 653).  This demonstrates how 
 Antiretroviral Therapy 34 
hunger can affect adherence to the drug regimen. Some healthcare facilities try to meet 
this need by supplying their patients with supplemental nutrient and protein-rich flour and 
foods.  
Pill Burden 
 Some patients may get tired of going to the hospital and taking pills on a regular  
basis. They may decide to take a break from it all. A Tanzanian who was interviewed 
commented on the discouragement some HIV patients on ART experience: “…one who 
can take them after some time gives up hope, [saying], ‘I have been taking these drugs for 
many days now and I think it is enough…if I am to be cured I will be cured and if not, 
then I don’t care even if I die, let me stop taking those drugs’” (Mshana, et al., 2006, p. 
653).  In addition, this is especially common in patients who are “feeling better.” They 
may not see a need to continue their medication (Mshana, et al., 2006).  Education is 
needed in this situation.  
Hospital-Related Factors 
 Sometimes patients are unwilling to begin or continue ART because they do not 
trust hospitals. They might be hesitant to go to hospitals because of the hospital’s 
reputation or because they have had a bad experience there in the past. For instance, 
information gained through interviews in one study revealed that some staff at medical 
facilities would demand bribes for access to healthcare. This deterred patients from 
returning (Mshana, et al., 2006).   
 Hospitals in Africa occasionally have the reputation of being “unfriendly and 
confusing.” The hospital experience can often be intimidating to people from smaller 
rural villages. Technology, large medical facilities, and doctors may be completely new 
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to villagers, which can be very daunting. Plus, less time can be spent on hospitality and 
patient education since there is a lack of healthcare providers. Therefore, patients may see 
doctors and nurses as being impersonal and/or ruthless. Yet, even if they are treated 
kindly, some patients may leave confused about their disease and the use of ART. 
Whether a patient has personally had negative experiences such as these, or heard about 
one from someone else, the hospital setting may deter him from going to the hospital to 
receive ART and maintain follow up appointments.   
In order to rectify some of the misconceptions, hospitals need to educate their 
staff about the potential problems and train them to treat their patients with kindness, 
dignity and respect. They should also receive additional training on patient education. 
The better patients understand the medical procedures and policies, the more comfortable 
they will be in healthcare facilities. Therefore, they will be more likely to return for 
follow-up visits and adherence will improve.  
 An additional factor that affects patient adherence is the long waiting time at the 
healthcare facilities. On average, patients will wait for 4 to 6 hours. In Hardon’s study, 
some patients had to wait as long as 10-12 hours. This can be very exhausting for 
patients, especially for those who traveled long distances to reach the facilities. Some 
patients leave without being seen due to discouragement and obligations at home 
(Hardon, et al., 2007).  A patient in Tanzania commented on this saying, “You may go 
there and be kicked like a ball. Maybe you arrive there and you give him/her your referral 
slip, you will wait a long time without being attended” (Mshana, et al., 2006).  Healthcare 
facilities need to address this issue to the best of their abilities. They need to evaluate  
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their appointment procedures. If a long waiting time is inevitable, they should warn their  
patients of this, and provide food and drinks at a low cost.  
Cultural Beliefs 
 Although most patients will not list cultural beliefs as one of their barriers to  
adherence, this is still a possibility in rural villages. Many beliefs regarding health and 
disease are passed down through the generations. Often this is not accurate medical 
information. Despite patient education in the hospitals or clinics, patients may still hold 
to traditional beliefs. This can distort their beliefs regarding the cause of HIV and the best 
way to treat it. In fact, 62% of medical providers included in Weiser et al.’s study in 
Botswana alleged that treatment adherence was often impeded by traditional etiologic 
explanation (Weiser, et al., 2003).  
Although Western medical practices are becoming more prevalent in Sub-Saharan 
Africa, many rural villages still use their traditional healer. In a study in Botswana, 21% 
of HIV patients expected that they would go to a traditional healer for HIV treatment in 
the future (Weiser, et al., 2003). Despite the fact that a patient may be receiving ART, he 
may consult his or her traditional healer as well. He might even feel pressure from the 
community to do so. The traditional healer will often give different recommendations 
than trained medical providers. Superstition is often a major component of traditional 
healer’s medical practices. Unfortunately, the patient might be advised to stop using 
ART, revise the regimen or use a traditional treatment instead. Therefore, this can 
become an obstacle to adherence. Patient education and community awareness are key in 
this situation. 
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Social Stigma 
Social stigma may affect patient adherence as well. In fact, in his study, Mshana  
suggested that “pervasive stigma remains the most formidable barrier” to distribution of 
ART and that it is “the backdrop to all difficulties in achieving a successful ARV 
programme” (Mshana, et al., 2006, p. 649, 653). Being HIV positive is viewed as very 
dishonorable and is often an immense disgrace on the family. Patients often feel guilty 
and ashamed. They may be afraid of disappointing family and friends. It is also possible 
that they will be blamed for passing on the virus to a partner, or for being unfaithful to a 
spouse (Mshana, et al., 2006). Sometimes employment is denied for these patients. In 
addition, these patients will often be abused, neglected, or rejected. (Kohi, Makoae, 
Chirwa, Holzemer, Phetlhu, Uys, et al., 2006). For example, in Hardon’s study, some 
patients in Botswana were treated badly by their spouse or even abandoned. In Uganda, 
some patients were isolated by members of the community (Hardon, et al., 2007).  In 
addition, one of the participants in Mshana’s study died due to neglect from her family 
and food deprivation (Mshana, et al., 2006).  
The fear that the social stigma instigates in Africans can often discourage people 
from being tested for HIV. Often people will not want to know because they are afraid 
that they would be positive for HIV. Instead of being properly tested, some people will 
weigh themselves on scales that line the streets. They will watch their weight to see if 
they are losing weight. This will give the person an idea if he is HIV positive without 
letting anyone else know.  
If a person knows that he is HIV positive, he may chose not to receive ART 
because of social stigma. In some cases, the person may be concerned about 
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confidentiality issues (Weiser, et al., 2003). In other situations, patients may decline ART 
because they do not feel they can comply with the treatment program’s regulations. For 
instance, in a study in Tanzania, the treatment program being studied required that 
patients have a “treatment buddy.” This treatment buddy would remind the patient to take 
his medication on a regular basis. Some patients refused treatment because they refused 
to disclose their diagnosis to anyone. They were afraid to choose a treatment buddy 
because of the social stigma (Mshana, et al., 2006).  
Even if patients agree to take ART, they may fear the negative outcomes from 
disclosing this information to the extent that they avoid telling anyone. In Weiser, et al.’s 
study, 94% of their patients kept their diagnosis of HIV a secret from their community. 
Furthermore, 69% of them kept their HIV status a secret from their family. This can 
greatly affect adherence to drug regimens (Weiser, et al., 2003).  
Since many patients do not disclose this information to anyone, it means that they 
will have to take their medication in secret. It can be difficult to find a time and place to 
be alone; therefore, it leads to inconsistency in taking their medication. In addition, these 
patients will not receive support and encouragement from their family to take their 
medication. If the patient’s family knows about their HIV status, there is a chance that 
they will be proactive and help them find transportation to the clinic or hospital and 
remind them to take their medication. However, due to the social stigma, some families 
will provide little to no support concerning their therapy; they may even ostracize them 
(Hardon, et al., 2007). In some cases, when children have HIV, the family may send them 
to school without their medications because they want to hide the fact that their child has 
HIV. This would also lead to poor adherence (Chesney, 2000).   
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Adherence is also affected by disclosure (or nondisclosure) of HIV status to 
patients’ employers. Patients take a risk when disclosing this information at their 
workplace. Some patients may lose their job or face other kinds of discrimination if their 
employers finds out. Each patient has to decide whether or not to tell his employer that he 
is HIV positive. If the employer does not know, the patient may not be able to get time 
off of work to go to the clinic or hospital for his follow-up visits and ART refills. 
However, if the patient tells his employer, he may lose his job, or the employer may not 
support his need for treatment and care. Therefore, the patient may not be able to adhere 
to his drug regimen because he cannot get time off to go to a healthcare facility (Hardon, 
et al., 2007). Social stigma needs to be targeted in a similar way to that of cultural 
issues—through education. First, healthcare providers need to assess the affects of social 
stigma in their communities. A possible assessment tool to use is provided in Appendix B 
(Hozemer, Uys, Chirwa,  Greeff, Makoae, Kohi, et al., 2007). Then whole communities 
need to be taught about HIV/AIDS and the importance of treatment. It is also important 
for the community’s leaders and influential people advocate for HIV testing and 
treatment.  
Poor Quality Counseling  
In order for patients to be able to adhere well to their ART drug regimen, they 
need to receive counseling and education. Without it, patients may not comprehend the 
importance of taking medication. Patients with insufficient counseling and education will 
be much less likely to continue taking their medication when they encounter side-effects 
and other barriers. They will also be more likely to quit taking the medication when they 
begin to feel well. In addition, they may not understand the drug regimen itself. For 
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instance, they may take their medication too often or too seldom. This results in poor 
adherence, increased vial load, and a higher risk of drug resistance. Many healthcare 
workers in clinics and hospitals of Sub-Saharan Africa do not have proper training in 
counseling. In a study that reviewed exit interviews, only 21% of patients on ART 
received counseling (Hardon, et al., 2007). Therefore, this is a major need in these 
healthcare facilities.  
Stenson, et al. devised a tool to assess patients’ need for counseling during their 
study in South Africa. Healthcare providers should use something similar to this tool 
routinely during their ART visits. This tool is included in Appendix C (Stenson, 
Charalambous, Dwadwa, Pemba, Du Toit, Baggaley, et al., 2005). HIV patients need to 
be taught about HIV itself, when to take the pill, how often to take the pill, and side 
effects of the medication. This helps the patient understand the situation and become 
more organized. They should also be counseled about the importance of adhering to the 
regimen, how to talk to family and friends about it, how to deal with the social stigma, 
and any other concerns that the patient may have. It may also be helpful to tailor the drug 
regimen to suit the patient’s life. One way to do this is to link particular daily activities 
with taking their medication (Chesney, 2000).  
Resistance to Drugs 
Despite the fact that antiretroviral therapy has been improving the lives of 
millions of HIV patients, a high concern for these patients is that they might become 
resistant to the medications. Drug resistance can become a major problem when patients 
do not adhere to their drug regimen. A study conducted by Laurent determined that 
approximately 12.5% of patients became resistant to at least one drug (Akileswaran,  
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Lurie, Flanigan, & Mayer, 2005). This problem is significant because when resistance  
develops, the patient has to be switched to a different drug regimen—second line 
treatments. This often costs about 10 times as much as the first line treatment (Hardon, et 
al., 2007). This makes it hard for the healthcare facilities in Sub-Saharan Africa to access 
and provide the necessary drugs.  
To address this concern, a program called the Global HIV Drug Surveillance 
Network is currently being developed to monitor global resistance and provide strategies 
to minimize resistance. The World Health Organization is collaborating with the 
International AIDS Society for this program (WHO, 2006). Research on resistance in 
sub-Saharan Africa is limited. However, data collected thus far has paralleled data from 
more developed countries such as the U.S. Multiple drug resistance has increased from 
1.1% of patients to 13.2% of patients in the United States between 1999 and 2001 (Vella 
& Palmisano, 2005). In order to prevent future cases of resistance, it is important to 
understand how resistance develops, determine which classes of ART patients most likely 
to become resistant to, and track and prevent resistance.   
There are multiple reasons why resistance develops. First of all, HIV has a very 
high turnover rate. In a chronic infection, half of the virons in the body are lost every 6 
hours. In order to make up for this loss, between 1 and 10 billion virons are produced on 
a daily basis. Secondly, there is a high likelihood of mutation. It is estimated that 10 
incorrect base pairs are incorporated into viral DNA every replication (Lehne, 2007).  
The high probability of error is due to the fact that HIV reverse transcriptase does not 
have a proofreading mechanism. Once a viron has mutated, it is harder for a drug to stop 
its replication. For instance, mutation can lead to a structural change in gp41 (the 
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glycoprotein on HIV’s envelope). This can prevent a fusion inhibitor from binding to it, 
making the drug ineffective. Or if a mutation causes HIV reverse transcriptase to change 
shape, the administration of NRTIs and NNRITs will be useless. As a result of varying 
mutations, many genetically different strains of HIV can be found within the same patient 
(Vella & Palmisano, 2005 & Lehne, 2007).   
If a patient has never been on antiretroviral therapy, drug-sensitive virons will 
greatly outnumber resistant virons. This is because the replication of “normal” virons is 
unopposed. Once ART is initiated, the drug prevents numerous viruses from replicating; 
the only surviving viruses are the less susceptible (or resistant) strains. These are the only 
ones that are able to continue replicating. This is similar to the idea of the “survival of the 
fittest.” Therefore, when a patient begins treatment, it is possible for him or her to quickly 
become drug-resistant. If resistance occurs, there is typically cross resistance with drugs 
within the same class (Vella & Palmisano, 2005).  
Two other major causes of resistance include poor patient adherence or a drug 
regimen with too low of a potency. These problems make it impossible to suppress the 
virus and allow the virus to replicate itself (Lehne, 2007). It is also important to note that 
HIV-2 (found in West Africa) is more resistant to medications. Therefore, treatment 
might be more difficult (Mullins, et al., 2004). 
The reason that physicians prescribe multiple medications for HIV is to prevent 
resistance. It is rare that a mutation in HIV could cause resistance to three or four 
different drugs at the same it. Each drug has a different target area which would require a 
mutation in order for the HIV strain to become drug resistant. One the other hand, it 
would be very easy for a patient to become resistant to a single drug used alone (Lehne, 
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2007).   
 Once resistance itself is understood, statistics regarding resistance to specific 
drugs need to be analyzed. Concerning individual classes of antiretroviral therapy, 
research shows that patients are most likely to develop resistance to NRTIs. The CATCH 
study in Europe compared resistance to each class of drug in treatment-naive patients 
(those who had never received ART beforehand). There results were as follows: NRTIs-
6.9% of patients, NNRTIs: 2.6%, protease inhibitors: 2.2%, and using a combination of at 
least two classes: 1.7% of patients (Vella & Palmisano, 2005). This showed which drugs 
patients are most likely to become resistant. In addition, it confirmed the idea that using a 
combination of drugs decreases the risk of resistance. Data collected by Laurent in Africa 
suggested the same order of resistance when comparing classes of drugs (Akileswaran et 
al., 2005).     
 Next, steps need to be taken to prevent drug resistance. Currently, most healthcare 
facilities in Sub-Saharan Africa do not have the resources and equipment necessary to 
test for resistance. Developing cheaper methods of testing for HIV resistance would be 
beneficial. In addition, there are a variety of other methods of preventing resistance that 
should be implemented. First of all, global research about the epidemic needs to be 
increased. As this information becomes organized, worldwide surveillance programs 
need to be in place so that the epidemic and treatment can be tracked. Secondly, patients 
need to be encouraged to adhere to their regimen—especially when on resistant-prone 
classes of drugs. Furthermore, it is important for patients to discontinue their ineffective 
drugs. Thirdly, since beginning drug therapy increases the risk of resistance, it is 
important to weigh the pros and cons on an individual basis before beginning a patient on 
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a particular regimen. Lastly, education about HIV and transmission should be continued. 
This is important because once a patient is drug-resistant, these are the strains of HIV that 
he or she can transmit to another person (Vella & Palmisano, 2005).   
 A main factor that reduces a patient’s chance of becoming resistance is 
maintaining optimal patient adherence. Possible suggestions were listed above and 
included ideas such as additional fundraising for patient expenses and providing 
transportation to healthcare facilities. In addition, patients should be provided with 
supplemental food, monitored for severe side-effects and be switched to a different 
regimen if needed. Finally, education of patients, providers and communities are 
necessities. Even though these suggestions will not eliminate all obstacles, they will make 
distribution and maintenance of ART regimens more feasible.  
Despite the multitude of possible obstacles, the use of ART in Sub-Saharan Africa 
is well worth the risk. Even though a complete cure may not be possible, putting more 
patients on ART will improve quality of life and increase life expectancy. Access to HIV 
can be improved by determining where the unmet need is and targeting the obstacles of 
providing treatment. Taking a proactive stance to do this will help to fight the devastating 
HIV epidemic that has been sweeping the globe.  
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Appendix A 
Antiretroviral Therapy Survey 
 
Please answer the following questions and return to Elizabeth Paquette at 
ejpaquette@liberty.edu.  
 
Thank you!   (Press Tab key to advance to next data entry field) 
 
1) What is your name/title?          
 
2) What country/city do you serve in?         
 
3) What is the name of your medical facility?       
 
4) Are you able to provide antiretroviral therapy for HIV/AIDS patients?                    
  yes        no 
If no, why not?        
If yes, continue please continue to answer questions 5-14. 
 
5) Approximately how many HIV/AIDS patients do you provide antiretroviral 
therapy for each year?       
 
6) Approximately what percent of HIV patients seeking treatment are you able to 
help?       
 
7) Who provides the funding for your facility? 
 Government 
 NGO 
 SIM Projects 
 Private grants 
Other (please specify)       
 
8) Are you able to provide antiretroviral therapy free of charge?    yes        no 
If not, what is the approximate cost for each patient?       
 
9) Which classes of drugs are available to you? (check all that apply) 
 NRTIs 
 NNRTIs 
 Protease Inhibitors 
 Fusion Inhibitors 
 
10) Which drug regimen do you use most frequently?       
 
11)  Does your facility have the capability of testing for resistance to drugs?    yes      
  no 
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 If not, please skip to question 14.   
 
12) Approximately what percent of the patients in your facility have become resistant 
to 1 or more drug?       
 
13)  Which is the most common class of drug that your patients have become resistant 
to? 
 NRTIs 
 NNRTIs 
 Protease Inhibitors 
 Fusion Inhibitors 
 
14) What major regulations does the government place on you in providing 
antiretroviral therapy? 
      
 
      
 
15)  Have you seen social stigma effect adherence to drug regimens?    yes        
no 
If so, in what ways?       
 
16) What major obstacles have you encountered while trying to provide treatment? 
(check all that apply) 
 Lack of funds 
 Lack of staff 
 Lack of facility 
 Antiretroviral drug availability 
 Government regulations 
 Geographic proximity to treatment facility 
 Patient adherence to drug regimen 
 Resistance to drugs 
 Social stigma and cultural issues 
Other (please specify)       
 
Comments: 
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Appendix B 
 
HIV/AIDS and Stigma Tool 
 
I’m going to read a list of events that may have happened to you during the past three months. After I read 
each item, please tell me how often it happened to you because of your HIV status: 
 
In the past 3 months, how often did the following events happen because of your HIV status? 
            Never      Once         Several        Most of   
                            or twice     times           the time 
1. I was told to use my own eating utensils.                                                                    
2. I was asked not to touch someone’s child.                                                                
3. I was made to drink last from the cup.                                            
4. Someone mocked me when I passed by.                                            
5. I stopped eating with other people.                                            
6. I was asked to leave because I was coughing.                                           
7. Someone stopped being my friend.                                            
8. A friend would not chat with me.                                            
9. I was called bad names.                                             
10. People sang offensive songs when I passed by.                                           
11. I was told that I have no future.                                             
12. Someone scolded me.                                              
13. I was told that God is punishing me.                                            
14. I was made to eat alone.                                             
15. Someone insulted me.                                              
16. People avoided me                                              
17. People cut down visiting me                                             
18. People ended their relationships with me                                           
19. I was blamed for my HIV status                                            
20. Someone tried to get me fired from my job.                                           
21. My employer denied me opportunities.                                            
 
 
The next set of questions is about your experiences in the hospital or clinic. In the past 3 months, how often 
did the following events happen because of your HIV status? 
 
Never     Once          Several       Most of 
               or twice      times          the time 
22. I was denied health care.                                             
23. I was refused treatment because I was told I was going                                         
to die anyway. 
24. I was discharged from the hospital while still needing care.                                         
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25. I was shuttled around instead of being helped by a nurse.                                          
26. At the hospital/clinic, I was made to wait until last                                         
27. At the hospital, I was left in a soiled bed.                                           
28. In the hospital or clinic, my pain was ignored.                                           
 
 
These questions are about some of your thoughts or feelings. How often have you thought or felt this way 
during the past 3 months because of your HIV status? 
 
Never       Once          Several      Most of  
                               or twice      times          the time 
29. I felt that I did not deserve to live.                                            
30. I felt ashamed of having this disease.                                            
 
(Hozemer, Uys, Chirwa,  Greeff, Makoae, Kohi, et al., 2007) 
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Appendix C 
 
Counseling Resource  
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(Stenson, Charalambous, Dwadwa, Pemba, Du Toit, Baggaley, et al., 2005) 
 
